Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Filipits, M; Pirker, R; Dunant, A; Lantuejoul, S; Schmid, K; Huynh, A; Haddad, V; André, F; Stahel, R; Pignon, JP; Soria, JC; Popper, HH; Le Chevalier, T; Brambilla, E.
Cell cycle regulators and outcome of adjuvant cisplatin-based chemotherapy in completely resected non-small-cell lung cancer: the International Adjuvant Lung Cancer Trial Biologic Program.
J Clin Oncol. 2007; 25(19): 2735-2740.
Doi: 10.1200/JCO.2006.08.2867
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
Google Scholar
- Co-Autor*innen der Med Uni Graz
- Popper Helmuth
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- PURPOSE: The International Adjuvant Lung Cancer Trial (IALT) demonstrated that adjuvant cisplatin-based chemotherapy improves the survival of patients with completely resected non-small-cell lung cancer (NSCLC). The purpose of our study was to determine whether cell cycle regulators are of prognostic and/or predictive value in patients who were enrolled onto the IALT. PATIENTS AND METHODS: Expression of p27Kip1, p16INK4A, cyclin D1, cyclin D3, cyclin E, and Ki-67 was immunohistochemically assessed in tumor specimens obtained from 778 IALT patients. Prognostic and predictive analyses were based on Cox models adjusted for clinical and pathologic parameters. RESULTS: There was a relationship between p27Kip1 status and benefit of cisplatin-based chemotherapy (test for interaction, P = .02). Among patients with p27Kip1-negative tumors, cisplatin-based chemotherapy resulted in longer overall survival compared with controls (adjusted hazard ratio [HR] for death = 0.66; 95% CI, 0.50 to 0.88; P = .006). In patients with p27Kip1-positive tumors, overall survival was not different between patients treated with cisplatin-based chemotherapy and controls (adjusted HR for death = 1.09; 95% CI, 0.82 to 1.45; P = .54). The other cell cycle regulators and Ki-67 did not predict benefit of adjuvant cisplatin-based chemotherapy. None of these biomarkers was significantly associated with overall survival of the patients in the total study population. CONCLUSION: NSCLC patients with p27Kip1-negative tumors benefit from adjuvant cisplatin-based chemotherapy after complete tumor resection. Before establishing p27Kip1 as a routine marker for selection of patients for adjuvant chemotherapy, the predictive value of p27Kip1 has to be confirmed in patients from other trials.
- Find related publications in this database (using NLM MeSH Indexing)
- Aged -
- Antineoplastic Agents - therapeutic use
- Carcinoma, Non-Small-Cell Lung - drug therapy
- Cell Cycle - drug therapy
- Chemotherapy, Adjuvant - drug therapy
- Cisplatin - therapeutic use
- Female - therapeutic use
- Gene Expression Regulation, Neoplastic - therapeutic use
- Humans - therapeutic use
- Intracellular Signaling Peptides and Proteins - metabolism
- Lung Neoplasms - drug therapy
- Male - drug therapy
- Middle Aged - drug therapy
- Prognosis - drug therapy
- Treatment Outcome - drug therapy